Structure Therapeutics Engages with Investors at Key Conferences
Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company, is gearing up to participate in important investor conferences this September. The company is dedicated to developing innovative oral small molecule therapeutics aimed at treating metabolic and cardiopulmonary diseases, reflecting its commitment to tackling significant healthcare challenges.
Upcoming Investor Conferences
The management team at Structure Therapeutics will connect with investors at several notable events:
Morgan Stanley 22nd Annual Global Healthcare Conference
The first event on their calendar is the Morgan Stanley 22nd Annual Global Healthcare Conference. Structure Therapeutics will be featured in a fireside chat on Thursday, September 5, at 10:00 a.m. EDT. This opportunity allows the management team to showcase the company’s innovative strategies and discuss its therapeutic pipeline.
Cantor Fitzgerald Global Healthcare Conference 2024
Additionally, Structure Therapeutics will participate in the Cantor Fitzgerald Global Healthcare Conference 2024. This event will also feature a fireside chat on Thursday, September 19, at 9:10 a.m. EDT. Engaging in these conferences highlights the company’s proactive approach to connecting with the investment community.
Accessing Live and Archived Webcasts
The company will offer live and archived webcasts of these fireside chats, which can be accessed via their official website. Investors and interested stakeholders are encouraged to tune in to these sessions to gain valuable insights into the company’s strategies, research, and advancements in the biopharmaceutical sector. Replays will be available for 90 days after the events, providing ample time for those unable to attend live.
About Structure Therapeutics
Founded on the principles of innovative science, Structure Therapeutics is dedicated to discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions. The company distinguishes itself in the biopharmaceutical industry through its next-generation structure-based drug discovery platform, which has facilitated the creation of a comprehensive GPCR-targeted pipeline. This pipeline features multiple proprietary clinical-stage compounds specifically designed to overcome the scalability challenges associated with traditional biologic and peptide therapies, ultimately making these treatments more accessible to patients around the globe.
Contact Information
For further information regarding investor relations or media inquiries, interested individuals can reach out to the following:
Investors:
Danielle Keatley
Structure Therapeutics Inc.
ir@structuretx.com
Media:
Dan Budwick
1AB
Dan@1abmedia.com
Frequently Asked Questions
What is Structure Therapeutics Inc. known for?
Structure Therapeutics Inc. specializes in developing innovative oral small molecule therapeutics for metabolic and cardiopulmonary diseases.
When will Structure Therapeutics participate in investor conferences?
The company will take part in conferences on September 5 and September 19.
How can I access the webcasts of the conferences?
Live and archived webcasts will be available on the Structure Therapeutics website for 90 days following the events.
Who should I contact for investor relations?
For inquiries related to investor relations, please contact Danielle Keatley at ir@structuretx.com.
What is the focus of the company's drug discovery platform?
The drug discovery platform is centered on GPCR-targeted therapies that address significant unmet medical needs in chronic conditions.